Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome

• Sponsor: M.D. Anderson Cancer Center (Other)
• Overall Status: Completed
• CT.gov ID: NCT00360672
• Collaborator: Celgene Corporation (Industry)
• Enrollment: 27
• Location: 1
• Arm: 1
• Duration (Months): 40
• Patients Per Site Per Month: 0.7

Study Details

Study Description

Brief Summary

The goal of this clinical research study is to find out if Revlimid can help to control the disease in patients with relapsed/refractory acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (MDS) with abnormalities in chromosome number 5. The safety of this treatment will also be studied.

Condition or Disease	Intervention/Treatment	Phase
Acute Myelogenous Leukemia; Myelodysplastic Syndrome	Drug: Revlimid	Phase 2

Detailed Description

Revlimid is designed to change the body's immune system. It may also interfere with the development of tiny blood vessels that help support tumor growth. It is possible that it may help reduce or prevent the growth of cancer cells.

You will have a bone marrow aspiration performed before starting treatment (within 4 weeks) on this study and at about 12 weeks after starting treatment on this study. Your doctor may also decide to perform a bone marrow aspiration before 12 weeks to assess your response to treatment. To collect a bone marrow aspirate, an area of the hip or chest bone is numbed with anesthetic, and a small amount of bone marrow is withdrawn through a large needle.

If you are found to be eligible to take part in this study, you will take Revlimid once a day by mouth (with a full glass of water, at least 1 hour before or after a meal) for 21 days.

You will then have 7 days off of the study drug, which is considered a rest period. This entire period is considered 1 cycle of therapy (28 days). The number of treatment cycles you may have will depend on the response of your disease to treatment on this study. You will have blood drawn (about 3 tablespoons) to test for blood counts and chemistries before each treatment cycle. At the end of 3 cycles, your disease will be evaluated for response to the study treatment.

You will be required to return to M. D. Anderson once a month for the first 3 months on this study or as often as the study doctor thinks it is best.

After the first 3 months on this study, you may have blood drawn (about 3 tablespoons) for blood counts and chemistries at your regular doctor's office. The results of your blood tests will then be sent to the research nurse. Your side effects will be reviewed by a doctor or nurse by telephone (in addition to being reviewed in your study diary) before the start of each cycle of treatment. This phone call will last about 10 minutes each time.

You will be taken off this study if your disease gets worse or you experience any intolerable side effects. It is also possible that the study doctor may decide to take you off this study if your disease response is considered less than a complete response. You will have an end-of-study visit, if you are taken off this study for any reason. During the end-of-study visit, you will have blood drawn (about 3 tablespoons) for blood counts and chemistries. You will have an ECG. You may have a urine pregnancy test. You will also have a bone marrow aspiration performed.

This is an investigational study. Revlimid® (lenalidomide) is indicated for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid® is also approved in combination with dexamethasone for the treatment of patients with multiple myeloma that have received at least one prior therapy. In this case it will be considered investigational. Up to 30 patients will take part in this study. All will be enrolled at M. D. Anderson.

Study Design

• Study Type: Interventional
• Actual Enrollment: 27 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase II Study of Lenalidomide in Patients With Relapsed/Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplastic Syndrome Associated With Chromosome 5 Abnormalities
• Study Start Date: Jan 1, 2009
• Actual Primary Completion Date: May 1, 2012
• Actual Study Completion Date: May 1, 2012

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Revlimid Revlimid 25 mg/day, orally for 21 days with 7 days rest (28 day cycle).	Drug: Revlimid; 25 mg/day, orally for 21 days with 7 days rest (28 day cycle).; Other Names: Lenalidomide CC-5013

Outcome Measures

Primary Outcome Measures

1. Number of Participants With a Response (Complete Remissions (CR), Complete Remissions With Incomplete Platelet Recovery [CRp] and Partial Responses) [Following three 28-day cycles evaluated for response]

   Response for Acute Myeloid Leukemia (AML) according to 2003 International Working Group (IWG) criteria: CR required absolute neutrophil count (ANC) >1 * 10^9/L, platelet count ≥100 * 10^9/L, < 5% of blast cells in bone marrow. CRp: as above except platelet count <100 * 10^9/L. Partial remission: as CR except for presence of 5-25% marrow blasts and with a decrease of marrow blast at least 50%. Response for Myelodysplastic Syndrome (MDS) was defined based on the 2006 IWG criteria. All participants with MDS who achieved hematological CR, Partial Response (PR), marrow CR, and hematological improvement considered responders.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. Understand and voluntarily sign an informed consent form.

2. Age >/= 18 years at the time of signing the informed consent form. (Revlimid has not been tested in younger patients)

3. Able to adhere to the study visit schedule and other protocol requirements.

4. Diagnosis of relapsed/refractory AML (other than APL) or high-risk MDS (IPSS categories intermediate-2 and high) with chromosome 5 abnormality as a sole abnormality or with additional abnormalities. MDS patients with blast percentage of

/= 10% will be considered high-risk.

1. All non-hematological toxicity of previous cancer therapy should have resolved to </= grade1 (except alopecia or other toxicities not involving major organs).

2. Should not have received any prior treatment for AML or MDS within 2 weeks of starting Revlimid. Use of hydrea to control proliferative disease will be allowed prior to starting Revlimid and for 7 days during cycles 1 and 2 (Maximum daily dose of 7gm).

3. Eastern Cooperative Oncology Group (ECOG) performance status of </ =2 at study entry

4. Laboratory test results within these ranges: • Serum creatinine </= 1.5 mg/dL • Total bilirubin </=1.5 mg/dL • aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) </=2 * upper limit of normal (ULN) or </=5 * ULN if related to disease

5. Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 milli-International unit (mIU)/mL within 10 - 14 days prior to and again within 24 hours of prescribing Revlimid (prescriptions must be filled within 7 days) and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 4 weeks before she starts taking Revlimid. FCBP must also agree to ongoing pregnancy testing.

6. (continued from above) Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy.

7. All study participants must be registered into the mandatory RevAssist® program, and be willing and able to comply with the requirements of RevAssist®.

8. Disease free of prior malignancies for >/ = 2 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "insitu" of the cervix or breast.

Exclusion Criteria:

1. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.

2. Pregnant or breast feeding females. (Lactating females must agree not to breast feed while taking Revlimid).

3. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.

4. Use of any other experimental drug or experimental therapy within 28 days of baseline.

5. Known hypersensitivity to thalidomide.

6. The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.

7. Any prior use of Revlimid.

8. Concurrent use of other anti-cancer agents or treatments. (Use of hydrea permitted as indicated in inclusion criterion 6)

9. Known positive for HIV or infectious hepatitis type B or C.

10. Heart rate less than or equal to 50.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	UT MD Anderson Cancer Center	Houston	Texas	United States	77030

Sponsors and Collaborators

• M.D. Anderson Cancer Center
• Celgene Corporation

Investigators

• Principal Investigator: Gautam Borthakur, MD, M.D. Anderson Cancer Center

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

• University of Texas MD Anderson Cancer Center

Publications

None provided.

• Responsible Party: M.D. Anderson Cancer Center
• ClinicalTrials.gov Identifier: NCT00360672
• Other Study ID Numbers: 2006-0293
• First Posted: Aug 7, 2006
• Last Update Posted: Aug 14, 2013
• Last Verified: Aug 1, 2013

• Keywords provided by M.D. Anderson Cancer Center: Acute Myelogenous Leukemia; Myelodysplastic Syndrome
• Additional relevant MeSH terms: Leukemia; Preleukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Syndrome; Lenalidomide

Study Results

Participant Flow

Recruitment Details	Recruitment Period: 08/03/2006 through 05/10/2012. All participants recruited at UT MD Anderson Cancer Center.

Arm/Group Title	Revlimid
Arm/Group Description	Revlimid 25 mg/day, orally for 21 days with 7 days rest (28 day cycle).
Period Title: Overall Study
STARTED	27
COMPLETED	27
NOT COMPLETED	0

Baseline Characteristics

Arm/Group Title	Revlimid
Arm/Group Description	Revlimid 25 mg/day, orally for 21 days with 7 days rest (28 day cycle).
Overall Participants	27
Age (years) [Median (Full Range) ]
Median (Full Range) [years]	64
Sex: Female, Male (Count of Participants)
Female	13 48.1%
Male	14 51.9%
Region of Enrollment (participants) [Number]
United States	27 100%

Outcome Measures

1. Primary Outcome

Title	Number of Participants With a Response (Complete Remissions (CR), Complete Remissions With Incomplete Platelet Recovery [CRp] and Partial Responses)
Description	Response for Acute Myeloid Leukemia (AML) according to 2003 International Working Group (IWG) criteria: CR required absolute neutrophil count (ANC) >1 * 10^9/L, platelet count ≥100 * 10^9/L, < 5% of blast cells in bone marrow. CRp: as above except platelet count <100 * 10^9/L. Partial remission: as CR except for presence of 5-25% marrow blasts and with a decrease of marrow blast at least 50%. Response for Myelodysplastic Syndrome (MDS) was defined based on the 2006 IWG criteria. All participants with MDS who achieved hematological CR, Partial Response (PR), marrow CR, and hematological improvement considered responders.
Time Frame	Following three 28-day cycles evaluated for response

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Revlimid
Arm/Group Description	Revlimid 25 mg/day, orally for 21 days with 7 days rest (28 day cycle).
Measure Participants	27
Complete Remission	1 3.7%
Complete Remission Incomplete Platelet Recovery	1 3.7%
Partial Remission	0 0%

Adverse Events

Time Frame	5 years, 8 months
Arm/Group Title	Revlimid
Arm/Group Description	Revlimid 25 mg/day, orally for 21 days with 7 days rest (28 day cycle).
All Cause Mortality
	Revlimid
	Affected / at Risk (%)	# Events
Total	/ (NaN)
Serious Adverse Events
	Revlimid
	Affected / at Risk (%)	# Events
Total	9/27 (33.3%)
Cardiac disorders
Atrial Fibrillation	3/27 (11.1%)	6
Gastrointestinal disorders
Vomit	1/27 (3.7%)	1
Hemorrhage	1/27 (3.7%)	1
General disorders
Death	5/27 (18.5%)	5
Infections and infestations
Infection	3/27 (11.1%)	3
Nervous system disorders
Stroke	2/27 (7.4%)	3
Renal and urinary disorders
Renal Failure	1/27 (3.7%)	1
Other (Not Including Serious) Adverse Events
	Revlimid
	Affected / at Risk (%)	# Events
Total	26/27 (96.3%)
Blood and lymphatic system disorders
Neutropenia	8/27 (29.6%)	8
Thrombocytopenia	14/27 (51.9%)	14
General disorders
Fatigue	3/27 (11.1%)	3
Infections and infestations
Neutropenic Fever	4/27 (14.8%)	4
Neutropenic Fever With Pneumonia	3/27 (11.1%)	3
Nonneutropenic Infection	13/27 (48.1%)	13

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.